BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26759237)

  • 1. RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway.
    Dubois F; Keller M; Calvayrac O; Soncin F; Hoa L; Hergovich A; Parrini MC; Mazières J; Vaisse-Lesteven M; Camonis J; Levallet G; Zalcman G
    Cancer Res; 2016 Mar; 76(6):1627-40. PubMed ID: 26759237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells.
    Keller M; Dubois F; Teulier S; Martin APJ; Levallet J; Maille E; Brosseau S; Elie N; Hergovich A; Bergot E; Camonis J; Zalcman G; Levallet G
    J Exp Clin Cancer Res; 2019 Apr; 38(1):158. PubMed ID: 30979377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition.
    Bousquet E; Calvayrac O; Mazières J; Lajoie-Mazenc I; Boubekeur N; Favre G; Pradines A
    Oncogene; 2016 Apr; 35(14):1760-9. PubMed ID: 26148238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
    Vlahov N; Scrace S; Soto MS; Grawenda AM; Bradley L; Pankova D; Papaspyropoulos A; Yee KS; Buffa F; Goding CR; Timpson P; Sibson N; O'Neill E
    Curr Biol; 2015 Dec; 25(23):3019-34. PubMed ID: 26549256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of YAP by NCTD disrupts NSCLC progression.
    Guo J; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Li X; Xi S
    Oncotarget; 2017 Jan; 8(2):2307-2319. PubMed ID: 27903989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation.
    Pefani DE; Pankova D; Abraham AG; Grawenda AM; Vlahov N; Scrace S; O' Neill E
    Mol Cell; 2016 Jul; 63(1):156-66. PubMed ID: 27292796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RHOB expression controls the activity of serine/threonine protein phosphatase PP2A to modulate mesenchymal phenotype and invasion in non-small cell lung cancers.
    Calvayrac O; Pradines A; Favre G
    Small GTPases; 2018 Jul; 9(4):339-344. PubMed ID: 27676292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circ_0078767 suppresses non-small-cell lung cancer by protecting RASSF1A expression via sponging miR-330-3p.
    Chen T; Yang Z; Liu C; Wang L; Yang J; Chen L; Li W
    Cell Prolif; 2019 Mar; 52(2):e12548. PubMed ID: 30507050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
    Burbee DG; Forgacs E; Zöchbauer-Müller S; Shivakumar L; Fong K; Gao B; Randle D; Kondo M; Virmani A; Bader S; Sekido Y; Latif F; Milchgrub S; Toyooka S; Gazdar AF; Lerman MI; Zabarovsky E; White M; Minna JD
    J Natl Cancer Inst; 2001 May; 93(9):691-9. PubMed ID: 11333291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control.
    Dubois F; Jean-Jacques B; Roberge H; Bénard M; Galas L; Schapman D; Elie N; Goux D; Keller M; Maille E; Bergot E; Zalcman G; Levallet G
    Cell Commun Signal; 2018 Oct; 16(1):66. PubMed ID: 30305100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma.
    Pankova D; Jiang Y; Chatzifrangkeskou M; Vendrell I; Buzzelli J; Ryan A; Brown C; O'Neill E
    EMBO J; 2019 Jul; 38(13):e100532. PubMed ID: 31268606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line.
    Sato N; Fukui T; Taniguchi T; Yokoyama T; Kondo M; Nagasaka T; Goto Y; Gao W; Ueda Y; Yokoi K; Minna JD; Osada H; Kondo Y; Sekido Y
    Int J Cancer; 2007 Feb; 120(3):543-51. PubMed ID: 17096327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
    Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
    Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
    Ahn EY; Kim JS; Kim GJ; Park YN
    Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of methylation status of RASSF1A gene as an independent factor of non-small cell lung cancer].
    Zhang H; Zhang S; Zhang Z; Jia H; Gu S; Zhao D
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):311-6. PubMed ID: 20677556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
    Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
    Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
    Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.